A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.

NCT Number	NCT07000357
Lead Sponsor	AstraZeneca
Conditions	Cardiovascular Disease
Enrollment	15,100 participants
Start Date	2025-06-04
Primary Completion	2029-10-26 (estimated)
Study Completion	2029-10-26 (estimated)
Updated on ClinicalTrials.gov	2026-07-02